Neurotech presentations at academic research conference in Cambridge, UK

Perth, Australia & Malta – 28 September 2017 – Neurotech International Limited (ASX: NTI) ("Neurotech" or the “Company”), developer of quality medical solutions in the neuroscience space, provided three presentations to academic researchers attending the 6th Cambridge International Conference on Mental Health, held between 20 - 22 September 2017 in Cambridge, UK.

These presentations were made at the same conference where Professor Frederik Carrick, a Senior Research Fellow with the Bedfordshire Centre for Mental Health Research (BCMHR) in association with the University of Cambridge, gave a presentation of preliminary findings of the independent, child autism study.

Representatives of Neurotech at the conference included Neurotech founder Dr Adrian Attard Trevisan, as well as senior research and development staff Dr Marco Rotonda and Dr Emanuela Russo. They covered various related topics, including:

- Electroencephalogram (“EEG”) phenotypes as basis for biomarker-driven personalised therapies (presented by Dr Attard Trevisan);
- Advances in high-definition transcranial direct current stimulation: a new pipeline to build anisotropic (directionally dependent) head models (presented by Dr Rotonda); and
- A home-based neurofeedback therapy for Autism Spectrum Disorder: A case study of a young adult patient (presented by Dr Russo).

These presentations are now available at the Mente website at http://www.mentetech.com/wp-content/uploads/2017/09/Cambridge-Presentations.pdf. The Company notes that the presentations are not of themselves considered material information but are more provided for general reference.

Following from this, Dr Attard Trevisan will also be interviewed by CNBC Asia on the morning 29th September.

Wolfgang Storf, CEO of Neurotech International said: “Our strong representation at the Cambridge conference is testament to the high level of research being carried out by our R&D staff and Dr Attard Trevisan. We give a lot of importance to research, and it is a key factor in our continued success as a developer of quality medical solutions.

We are of course also very excited with Professor Carrick’s presentation of the preliminary findings of the independent study undertaken with Mente Autism as announced yesterday. In particular, their statements that the preliminary results demonstrated positive changes in children's neurological function after using the Mente Autism device is very encouraging. The changes observed in autistic children after a 12-week clinical trial were outstanding with many of the children with autism scoring in a normal range after the treatment. Our Company shares the view that Mente Autism will provide new hope for therapy for autistic children using the device.”

-ends-
About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:


For more information please contact:

Matthew Wright
matt@nwrccommunications.com.au
Tel: +61 451 896 420